RAF1 and melanoma: GSK2118436 (a.k.a. dabrafenib) is an ATP-competitive inhibitor of mutant B-Raf, WT B-Raf and WT Raf-1 developed by GlaxoSmithKlein (GSK) in clinic trial (NCT00880321), which examined patients with melanoma, brain metastases, in other solid tumours it was determined to be safe and elicited responses.